CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American heart journal Gutierrez, J. A., Heizer, G. M., Jones, W. S., Rockhold, F. W., Mahaffey, K. W., Fowkes, F. G., Berger, J. S., Baumgartner, I. n., Held, P. n., Katona, B. G., Norgren, L. n., Blomster, J. I., Hiatt, W. R., Patel, M. R. 2020; 229: 118–20

View details for DOI 10.1016/j.ahj.2020.07.017

View details for PubMedID 32950849